Amgen has sealed an agreement with Inovalon, a specialist in health data analytics, to develop outcomes based contracts based on the value of Amgen’s products.
The agreement will focus specifically on rheumatoid arthritis, a chronic, high-cost autoimmune disease affecting more than two million Americans. As the healthcare landscape continues to rapidly transform from fee-for-service and volume-based models, to value and outcomes-based models, outcomes-based contracts have become increasingly prevalent in the marketplace.
Inovalon’s outcomes-based contracting platform supports the creation, deployment and management of value-based contracts between payers and life sciences companies, using data aggregation and management, predictive analytics, data-driven patient and provider engagement platforms, and data reporting capabilities.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.